You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Positive trial results boost Vertex

Shares of Vertex Pharmaceuticals Inc. soared more than 55.5 percent in after-hours trading on the Nasdaq stock market Thursday after the Cambridge biotechnology company released positive clinical data on an experimental cystic fibrosis treatment.

Vertex said a midstage study of its VX-661 drug candidate in combination with its approved cystic fibrosis drug Kalydeco “showed statistically significant improvements in lung function” in adult patients.

Continue reading below

“These new results provide further validation of our strategy” of combining therapies to develop a portfolio of treatments for patients with different forms of cystic fibrosis, Vertex chief executive Jeffrey Leiden said in a conference call with investors.

The life-threatening disease, passed down through families, causes mucus to build up in the lungs and digestive tract.

Vertex stock closed down 2.2 percent at $52.87 in Thursday trading. But when Vertex released its clinical data after the market closed, the share price quickly vaulted more than $29.

Robert Weisman can be reached at weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.